thomas keuer arca biopharma inc profile  biography  bloomberg feedback thomas keuer chief operating officer arca biopharma inc career history chief operating officer arca biopharma inc present exec vppharmaceutical ops arca biopharma inc  senior vpoperations insmed inc  senior vptherapeutic proteins insmed inc  vpengineering baxter healthcare  vpoperations somatogen inc former show more website wwwarcabiopharmacom corporate information address  arista place suite  broomfield co  united states phone  fax  web url wwwarcabiopharmacom from the web personal information education william marsh rice university masters degree the university of texas system bachelors degree sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data thomas keuer  arca biopharma inc  zoominfocom keuer thomas a  the wall street transcript thomas a keuer thomas a keuer is chief operating officer of arca biopharma inc mr keuer was appointed to his current position as chief operating officer in december  he joined arca in october  as executive vice president pharmaceutical operations prior to joining arca mr keuer held a number of senior leadership positions in the biopharmaceutical industry including svp of operations for insmed vp of engineering for baxter healthcare and vp of operations for somatogen mr keuer completed his undergraduate degree in chemical engineering at the university of texas austin and his ms degree in biochemical engineering at rice university related interviewsinterview with the coo arca biopharma inc nasdaqabiomarch   cartlatest newsjames abate of centre asset management sees consumer demand driving new stock highsmalcolm e polley of stewart capital and how to play the health care stockstimothy biltz ceo of lumos networks identifies the key component for future g networksthe wall street transcript is a completely unique resource for investors and business researchersover  ceo equity analyst and money manager interviewssubscribe nowsign up for newsletter weekly email with new indepth interviews email most popular interviewsdelivering longterm results with a riskmanaged growth fundjames a abate published july   in investing strategiescompanies covered amat jnj coh rl cog nvda adbe atvi klac amzn nflx goog fb glw mu   wfm jwn cmg gps eqt rice spls buy finding investments with favorable risk and reward opportunitieshenry beukema published july   in investing strategiescompanies covered orcl msft nsrgy amzn wfm lrlcy agn lnr buy better returns and lower risk in the midcap spacemalcolm e polley published july   in investing strategiescompanies covered praa hurn fii fl nke amzn wfm wba rad buy most popular reportswireless communications  telecom published july  buy investing strategies published july  buy investing strategies published june  buy  top company interviews register for a free account to gain greater access to the wall street transcript right now ceo interviewsinterview with the president and ceo lumos networks corp nasdaqlmosinterview with the corporate vp of business development strategy and investor relations dsp group inc nasdaqdspginterview with the ceo and director tactile systems technology inc nasdaqtcmd sector roundtablesnatural gas weighs heavy on ep nearterm prospectsroundtable forumoptimism despite uncertainty in forprofit educationroundtable foruma shift in focus to natural gas from oil money manager interviewsdelivering longterm results with a riskmanaged growth fundfinding investments with favorable risk and reward opportunitiesbetter returns and lower risk in the midcap space analyst interviewsanalyzing the secular drivers within communications infrastructure and telecomsatellite companies benefiting from growth in data trafficincreased focus on content as consumers shift to digital consumption subscribe today since   the wall street transcript  terms and conditions privacy policy   httpswwwtwstcomwpadminadminajaxphp pin it on pinterest share this twitter facebook google gmail linkedin × join now for free already a member first name last name email address  create new account or create an account with a social network join with facebook join with twitter join with google username or email address  password  loginjoin now  forgot password or login using a social network log in with facebook log in with twitter log in with google arca discovery inc names thomas keuer executive vice president of pharmaceutical operations employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       arca discovery inc names thomas keuer executive vice president of pharmaceutical operations tweet   am denver oct  prnewswire  arca discovery inc a privately held biopharmaceutical company developing geneticallytargeted therapies for heart failure and other cardiovascular diseases today announced the appointment of thomas a keuer as executive vice president of pharmaceutical operations mr keuer has over twenty five years of experience in the biotechnology and pharmaceutical industries at insmed inc baxter international somatogen and monsanto most recently he served as senior vice president insmed therapeutic proteins with responsibility for all aspects of the therapeutic protein manufacturing program and boulder site prior to that he held the position of vice president of engineering for the biosciences division of baxter international mr keuer received his masters of science in biochemical engineering from rice university as a monsantosponsored delegate in making the announcement arcas president and chief executive officer dr michael r bristow said we are very pleased to have tom keuer join the arca team he brings to the company the operational expertise experienced leadership and knowledge in chemistry manufacturing  controls that we need to meet the regulatory challenges of drug development and prepare for commercialization of our lead product bucindolol i believe that arcas approach for development of targeted optimized therapies for cardiovascular disease will represent a major advancement in personalized medicine i look forward to working with the arca team to commercialize bucindolol and provide this important therapy to the patients who need it said mr keuer about arca discovery inc arca discovery inc is a privately held biopharmaceutical company developing geneticallytargeted therapies for heart failure and other cardiovascular diseases the companys first product is bucindolol a third generation betablockervasodilator for advanced heart failure and other indications that promises to be the first geneticallytargeted cardiovascular drug bucindolol has extensive phase iii data and a unique phase iii dna substudy using this substudy arcas founding scientists have confirmed two genetic polymorphisms that interact with bucindolols unique pharmacology to modify patient response arca is preparing an nda for bucindolol and intends to seek fda approval of bucindolol during  arca discovery inc contact michael bristow md phd president and chief executive officer ofarca discovery inc  read at biospacecom related news arca discovery inc announces publication of the genetic basis for enhanced response to bucindolol biomed company announces expansion in iowa national genecular institute will add  jobs arca discovery inc names dr ann lenich hards executive vice president regulatory affairs sanofiaventis france sasypa to cut  jobs in france arca discovery inc raises  million in series a financing martek biosciences corporation matk announces restructuring of plant operations and updates revenue guidance aeolus pharmaceuticals inc aolsob receives  milestone payment and equity interest from cardiovascular company critical therapeutics inc crtx outlines new business strategy focusing on controlledrelease and intravenous formulations of zileuton company announces restructuring of us sales force and rd group incara pharmaceuticals corp incr and indevus pharmaceuticals inc idev outlicense bucindolol interest for developmentacadia pharmaceuticals inc acad to support launch of new company focused on substance abuse therapeutics mark r brann phd to become ceo of abbey pharmaceuticals please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • arca discovery inc   • biotechpharma  personnel                       insider trading  keuer thomas a  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  keuer thomas a select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing sale  pm arca biopharma inc abio keuer thomas achief operating officer    direct view sale  pm arca biopharma inc abio keuer thomas achief operating officer    direct view sale  pm arca biopharma inc abio keuer thomas achief operating officer    direct view sale  pm arca biopharma inc abio keuer thomas achief operating officer    direct view sale  pm arca biopharma inc abio keuer thomas achief operating officer    direct view sale  pm arca biopharma inc abio keuer thomas achief operating officer    direct view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing option award  pm na arca biopharma inc abio keuer thomas achief operating officer   direct view option award  pm na arca biopharma inc abio keuer thomas achief operating officer   direct view option award  pm nana arca biopharma inc abio keuer thomas achief operating officer   direct view option award  pm na arca biopharma inc abio keuer thomas achief operating officer   direct view   secformcom all rights reserved archives        sat  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  abio thomas a keuer insider trades for arca biopharma inc bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close arca biopharma inc nasdaq abio go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus arca biopharma inc market closed  quotes are delayed by  min jul    pm abio quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual thomas a keuer mr thomas a keuer is chief operating officer at arca biopharma inc mr keuer was previously employed as executive vice presidentpharmaceutical operations by arca biopharma inc old vice presidentengineering by baxter international inc senior vice president by insmed inc and vice presidentoperations by somatogen inc he received his undergraduate degree from the university of texas and a graduate degree from rice university transactions date shares transaction value     disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      award at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives dr michael r bristow president chief executive officer  director mr thomas a keuer chief operating officer mr brian l selby chief accounting officer  vice presidentfinance mr christopher david ozeroff secretary senior vice president  general counsel dr anders d hove director mr derek k cole investor relations  media contact dr raymond l woosley independent director mr dan j mitchell independent director log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest ptrump says he has ‘complete power to pardon’ plawmakers reach deal on russia sanctions bill reports palphabet earnings a  billion hit for google potential youtube results for investors pyou can date someone who looks just like donald trump with this new online service pwant to buy happiness splurge on these  things pthis is what people really buy when they emotionally overspend hint it’s not designer clothes pjohn mccain is a war hero — but think twice before saying he’s ‘battling’ cancer pthe dark side of cruises pi want to buy my brothers out of our family home — but they want me to pay future sales fees poj simpson made over  while in prison and won’t have to give any of it to the goldman family pnot even free money can make some people go to the gym phow realestate tv shows determine what buyers look for in a house pwhat eleanor roosevelt and helen gurley brown ate — and what we can learn from it pnote to parents this social network was rated the worst for teenage cyberbullying pif like sean spicer you suddenly quit your job — what should you do next pthis is the deadliest time of your life to put on weight p unfortunate reasons why millennials can’t have nice things or save any money pus giving takeover bids by chinese firms much tougher look pjared kushner discloses dozens of additional assets in revised filing pbitcoin surges as miners avert split for now loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  arca biopharma inc abioo people  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states arca biopharma inc abioo related topics stocksstock screenermarket datahealthcarepharmaceuticals overview news key developments people charts financials analysts research pulse abioo on consolidated issue listed on nasdaq capital market usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  summary name age since current position robert conway   chairman of the board michael bristow   president chief executive officer director thomas keuer   chief operating officer christopher ozeroff   senior vice president general counsel secretary brian selby   chief accounting officer principal accounting officer vice president  finance linda grais  lead independent director anders hove   director daniel mitchell   director raymond woosley   director » insider trading biographies name description robert conway mr robert e conway has been appointed as chairman of the board of arca biopharma inc with effect from june   he serves on the audit and compensation committees of the board of directors mr conway has over  years of executive leadership experience in the pharmaceutical and biotechnology industries mr conway served as the chief executive officer and member of the board of directors of array biopharma from  to  array is a biopharmaceutical company focused on the discovery development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases prior to joining array mr conway was the chief operating officer and executive vice president of hill top research inc a clinical research services company from  to  he also held various executive positions for corning inc including corporate vice president and general manager of corning hazleton inc a contract research organization mr conway serves as the chairman of wall family enterprise a leading library and education supplies company he is on the board of directors of eresearch technology inc in addition mr conway is a member of the strategic advisory committee of genstar capital llc michael bristow dr michael r bristow phd md is president chief executive officer director of arca biopharma inc prior to that time dr bristow served as the company’s chief science and medical officer and a director since the merger with nuvelo dr bristow has also served as a director of arca colorado since november  dr bristow was one of the founders of arca colorado in september  and served as its chairman and chief executive officer from that date until he was appointed to the position of chief science and medical officer in november  dr bristow is a professor of medicine and the former head of cardiology at the university of colorado health sciences center where he has been since october  dr bristow was one of the founders of myogen inc and served as myogen’s chief science and medical officer from october  to february  and as a scientific advisor to myogen from february  until the acquisition of myogen by gilead sciences inc in november  dr bristow also has experience with and knowledge of arca’s business as the founder and former chief science and medical officer of arca colorado and the current president and chief executive officer of the company and as a board member of arca colorado since  and of the company since january  thomas keuer mr thomas keuer is chief operating officer of the company mr keuer has been arca’s executive vice president pharmaceutical operations for the past  years prior to joining arca mr keuer served in a number of senior leadership positions in the biopharmaceutical industry including svp of operations for insmed inc vp of engineering for baxter healthcare and vp of operations for somatogen inc mr keuer received his ms in biochemical engineering from rice university and received his bs in chemical engineering from the university of texas austin christopher ozeroff mr christopher david ozeroff is senior vice president general counsel secretary of arca biopharma incpreviously mr ozeroff served as the company’s executive vice president of business development general counsel and secretary since the merger with nuvelo before the merger mr ozeroff was one of the founders of arca colorado in september  and had served as its executive vice president of business development general counsel and secretary since that date from august  mr ozeroff was previously a partner with the law firm of hogan  hartson llp where he practiced in such areas as finance acquisitions public offerings and licensing mr ozeroff completed his undergraduate degree at stanford university and his law degree at the university of chicago law school brian selby mr brian selby is chief accounting officer vice president  finance of the company prior to joining arca he worked at several public companies including controller for myogen inc and controller for genomica corporation linda grais dr linda grais md is lead independent director of arca biopharma inc she has served as a member of the company’s board of directors since the merger with nuvelo in january  before the merger dr grais had served as a director of arca colorado since may  dr grais served as a managing member at interwest partners a venture capital firm from may  until february  from july  to july  dr grais was a founder and executive vice president of sgx pharmaceuticals inc a drug discovery company focusing on new treatments for cancer prior to that she was a corporate attorney at wilson sonsini goodrich  rosati where she practiced in such areas as venture financings public offerings and strategic partnerships before practicing law dr grais worked as an assistant clinical professor of internal medicine and critical care at the university of california san francisco dr grais received a ba from yale university magna cum laude and phi beta kappa an md from yale medical school and a jd from stanford law school anders hove dr anders hove md serves as director of the company dr hove was also appointed to serve on the board’s nominating and corporate governance committee dr hove was most recently a general partner of venrock associates “venrock” a venture capital firm which he joined in january  in  dr hove was a founder of venrock healthcare capital partners venrock’s public fund focused on small capitalization biotech companies and latestage private companies from  to  he was a fund manager at bb biotech fund an investment firm and from  to  he also served as chief executive officer of bellevue asset management llc an investment company dr hove previously held senior level positions in the medical clinical and business operations of the pharmaceuticals division of cibageigy he has served on the boards of directors of numerous private and public companies currently serving on the boards of two private biopharmaceutical companies dr hove received a msc in biotechnology engineering from the technical university of denmark an md from the university of copenhagen and an mba from the institut européen dadministration des affaires daniel mitchell mr daniel j mitchell is director of the company mr mitchell founded and is a manager of sequel venture partners llc a venture capital firm formed in january  prior to founding sequel venture partners mr mitchell was a founder in  of capital health venture partners a health care focused venture capital firm where he was a general partner until  on behalf of sequel ventures mr mitchell led the  series a financing that initially funded myogen inc a biopharmaceutical company focused on cardiovascular diseases participated in subsequent financing rounds and served on the board of directors until myogen was acquired in  he served on the board of directors of replidyne inc a publiclytraded pharmaceutical company from  until the company was acquired in  mr mitchell currently serves on the board of directors of several private companies mr mitchell holds a bs from the university of illinois and an mba from the university of california at berkeley raymond woosley dr raymond l woosley md phd has been appointed as director of arca biopharma inc effective july   dr woosley is currently the president emeritus of the critical path institute cpath a nonprofit publicprivate partnership with the united states food and drug administration of which he was a founder and where he served as president chief executive officer and chairman of the board from  to  since  dr woosley is also the president and chairman of the board of the arizona center for education and research on therapeutics azcert an independent nonprofit research and education organization dedicated to the safe use of medicines since  dr woosley has also been a professor of medicine and pharmacology at the university of arizona health sciences center and professor emeritus since  where he was also vice president for health sciences from  to  and dean of the college of medicine from  to  from  to  dr woosley was a professor of pharmacology and medicine at the georgetown university school of medicine where he was also director of the institute of cardiovascular sciences from  to  and division chief clinical pharmacology in the department of medicine from  to  dr woosley earned his phd in pharmacology from the university of louisville and his md from the university of miami basic compensation name fiscal year total robert conway  michael bristow  thomas keuer  christopher ozeroff  brian selby  linda grais  anders hove  daniel mitchell  raymond woosley  as of   dec  options compensation name options value robert conway   michael bristow   thomas keuer   christopher ozeroff   brian selby   linda grais   anders hove   daniel mitchell   raymond woosley   insider trading name shares traded price conway robert e   mitchell daniel j   bristow michael r   ozeroff christopher david   keuer thomas a   selby brian l   conway robert e   ozeroff christopher david   bristow michael r   keuer thomas a   selby brian l   keuer thomas a   keuer thomas a   bristow michael r   ozeroff christopher david   selby brian l   keuer thomas a   ozeroff christopher david   bristow michael r   selby brian l   keuer thomas a   ozeroff christopher david   bristow michael r   selby brian l   keuer thomas a   » full list on insider trading related topics stocksstock screenermarket datahealthcarepharmaceuticals edward keuer   zoominfocom arca biopharma inc abioph people  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states arca biopharma inc abioph related topics stocksstock screenermarket datahealthcarepharmaceuticals overview news key developments people charts financials analysts research pulse abioph on philadelphia stock exchange usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  summary name age since current position robert conway   chairman of the board michael bristow   president chief executive officer director thomas keuer   chief operating officer christopher ozeroff   senior vice president general counsel secretary brian selby   chief accounting officer principal accounting officer vice president  finance linda grais  lead independent director anders hove   director daniel mitchell   director raymond woosley   director » insider trading biographies name description robert conway mr robert e conway has been appointed as chairman of the board of arca biopharma inc with effect from june   he serves on the audit and compensation committees of the board of directors mr conway has over  years of executive leadership experience in the pharmaceutical and biotechnology industries mr conway served as the chief executive officer and member of the board of directors of array biopharma from  to  array is a biopharmaceutical company focused on the discovery development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases prior to joining array mr conway was the chief operating officer and executive vice president of hill top research inc a clinical research services company from  to  he also held various executive positions for corning inc including corporate vice president and general manager of corning hazleton inc a contract research organization mr conway serves as the chairman of wall family enterprise a leading library and education supplies company he is on the board of directors of eresearch technology inc in addition mr conway is a member of the strategic advisory committee of genstar capital llc michael bristow dr michael r bristow phd md is president chief executive officer director of arca biopharma inc prior to that time dr bristow served as the company’s chief science and medical officer and a director since the merger with nuvelo dr bristow has also served as a director of arca colorado since november  dr bristow was one of the founders of arca colorado in september  and served as its chairman and chief executive officer from that date until he was appointed to the position of chief science and medical officer in november  dr bristow is a professor of medicine and the former head of cardiology at the university of colorado health sciences center where he has been since october  dr bristow was one of the founders of myogen inc and served as myogen’s chief science and medical officer from october  to february  and as a scientific advisor to myogen from february  until the acquisition of myogen by gilead sciences inc in november  dr bristow also has experience with and knowledge of arca’s business as the founder and former chief science and medical officer of arca colorado and the current president and chief executive officer of the company and as a board member of arca colorado since  and of the company since january  thomas keuer mr thomas keuer is chief operating officer of the company mr keuer has been arca’s executive vice president pharmaceutical operations for the past  years prior to joining arca mr keuer served in a number of senior leadership positions in the biopharmaceutical industry including svp of operations for insmed inc vp of engineering for baxter healthcare and vp of operations for somatogen inc mr keuer received his ms in biochemical engineering from rice university and received his bs in chemical engineering from the university of texas austin christopher ozeroff mr christopher david ozeroff is senior vice president general counsel secretary of arca biopharma incpreviously mr ozeroff served as the company’s executive vice president of business development general counsel and secretary since the merger with nuvelo before the merger mr ozeroff was one of the founders of arca colorado in september  and had served as its executive vice president of business development general counsel and secretary since that date from august  mr ozeroff was previously a partner with the law firm of hogan  hartson llp where he practiced in such areas as finance acquisitions public offerings and licensing mr ozeroff completed his undergraduate degree at stanford university and his law degree at the university of chicago law school brian selby mr brian selby is chief accounting officer vice president  finance of the company prior to joining arca he worked at several public companies including controller for myogen inc and controller for genomica corporation linda grais dr linda grais md is lead independent director of arca biopharma inc she has served as a member of the company’s board of directors since the merger with nuvelo in january  before the merger dr grais had served as a director of arca colorado since may  dr grais served as a managing member at interwest partners a venture capital firm from may  until february  from july  to july  dr grais was a founder and executive vice president of sgx pharmaceuticals inc a drug discovery company focusing on new treatments for cancer prior to that she was a corporate attorney at wilson sonsini goodrich  rosati where she practiced in such areas as venture financings public offerings and strategic partnerships before practicing law dr grais worked as an assistant clinical professor of internal medicine and critical care at the university of california san francisco dr grais received a ba from yale university magna cum laude and phi beta kappa an md from yale medical school and a jd from stanford law school anders hove dr anders hove md serves as director of the company dr hove was also appointed to serve on the board’s nominating and corporate governance committee dr hove was most recently a general partner of venrock associates “venrock” a venture capital firm which he joined in january  in  dr hove was a founder of venrock healthcare capital partners venrock’s public fund focused on small capitalization biotech companies and latestage private companies from  to  he was a fund manager at bb biotech fund an investment firm and from  to  he also served as chief executive officer of bellevue asset management llc an investment company dr hove previously held senior level positions in the medical clinical and business operations of the pharmaceuticals division of cibageigy he has served on the boards of directors of numerous private and public companies currently serving on the boards of two private biopharmaceutical companies dr hove received a msc in biotechnology engineering from the technical university of denmark an md from the university of copenhagen and an mba from the institut européen dadministration des affaires daniel mitchell mr daniel j mitchell is director of the company mr mitchell founded and is a manager of sequel venture partners llc a venture capital firm formed in january  prior to founding sequel venture partners mr mitchell was a founder in  of capital health venture partners a health care focused venture capital firm where he was a general partner until  on behalf of sequel ventures mr mitchell led the  series a financing that initially funded myogen inc a biopharmaceutical company focused on cardiovascular diseases participated in subsequent financing rounds and served on the board of directors until myogen was acquired in  he served on the board of directors of replidyne inc a publiclytraded pharmaceutical company from  until the company was acquired in  mr mitchell currently serves on the board of directors of several private companies mr mitchell holds a bs from the university of illinois and an mba from the university of california at berkeley raymond woosley dr raymond l woosley md phd has been appointed as director of arca biopharma inc effective july   dr woosley is currently the president emeritus of the critical path institute cpath a nonprofit publicprivate partnership with the united states food and drug administration of which he was a founder and where he served as president chief executive officer and chairman of the board from  to  since  dr woosley is also the president and chairman of the board of the arizona center for education and research on therapeutics azcert an independent nonprofit research and education organization dedicated to the safe use of medicines since  dr woosley has also been a professor of medicine and pharmacology at the university of arizona health sciences center and professor emeritus since  where he was also vice president for health sciences from  to  and dean of the college of medicine from  to  from  to  dr woosley was a professor of pharmacology and medicine at the georgetown university school of medicine where he was also director of the institute of cardiovascular sciences from  to  and division chief clinical pharmacology in the department of medicine from  to  dr woosley earned his phd in pharmacology from the university of louisville and his md from the university of miami basic compensation name fiscal year total robert conway  michael bristow  thomas keuer  christopher ozeroff  brian selby  linda grais  anders hove  daniel mitchell  raymond woosley  as of   dec  options compensation name options value robert conway   michael bristow   thomas keuer   christopher ozeroff   brian selby   linda grais   anders hove   daniel mitchell   raymond woosley   insider trading name shares traded price conway robert e   mitchell daniel j   bristow michael r   ozeroff christopher david   keuer thomas a   selby brian l   conway robert e   ozeroff christopher david   bristow michael r   keuer thomas a   selby brian l   keuer thomas a   keuer thomas a   bristow michael r   ozeroff christopher david   selby brian l   keuer thomas a   ozeroff christopher david   bristow michael r   selby brian l   keuer thomas a   ozeroff christopher david   bristow michael r   selby brian l   keuer thomas a   » full list on insider trading related topics stocksstock screenermarket datahealthcarepharmaceuticals